Development | Peptides | Tirzepatide
Tirzepatide
Tirzepatide is a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is used for the treatment of type 2 diabetes and obesity, demonstrating high efficacy in blood sugar control and weight reduction. By combining the benefits of both hormones, tirzepatide stands out as a unique therapeutic agent in its class.

The peptide is a tirzepatide molecule produced through genetic engineering synthesis using Escherichia coli cells. The drug's structure incorporates modifications to extend its half-life in the body. In addition to amino acid substitutions that prevent degradation by peptidases, a C20 diacid fatty acid is attached to the peptide to optimize absorption and metabolism

Mechanism of Action:
GLP-1 Receptor Effects

• Stimulates insulin secretion in response to food intake, lowering blood sugar levels
• Slows gastric emptying, promoting prolonged satiety
• Reduces appetite by acting on hunger centers in the brain

GIP Receptor Effects

• Improves cellular insulin sensitivity
• Enhances weight loss by increasing energy expenditure and reducing fat accumulation

АAdvantages:

• Superior Blood Sugar Control
• Clinical studies confirm tirzepatide's significant improvement in glycemic management.
• Remarkable Weight Reduction
• The drug demonstrates impressive results in body weight reduction, making it particularly beneficial for patients with obesity.